MedTrace Logo

To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures

NCT00552305 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 370

Last updated 2018-07-17

Study results available
· View outcomes & findings →

Summary

The purpose of this trial is to determine whether lacosamide is safe and effective for long-term use in patients with partial-seizures from epilepsy.

Conditions

  • Partial Epilepsies

Interventions

DRUG

lacosamide

50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing throughout the trial

Sponsors & Collaborators

  • UCB Pharma

    lead INDUSTRY

Principal Investigators

  • UCB Clinical Trial Call Center · +1 877 822 9493 (UCB)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-08-31
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • United States
  • Germany
  • Hungary
  • Lithuania
  • Poland
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00552305 on ClinicalTrials.gov